You are here: Industry Insights > Metabolic Disorders

News List

Lilly and Regor Therapeutics Collaborate to Discover and Develop Novel Therapies for Metabolic Disorders AmericanPharmaceuticalReview
December 13, 2021
Eli Lilly and Company and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders.
Lilly and Regor sign deal to develop treatments for metabolic disorders Pharmaceutical-Technology
December 13, 2021
Eli Lilly and Company and Regor Therapeutics Group have signed an agreement to discover, develop and market new treatments for metabolic disorders.
Lumen Bioscience and Novo Nordisk Collaborate on Research of Biologics for Cardiometabolic Disease americanpharmaceuticalreview
June 18, 2021
Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for prevalent diseases, will collaborate with Novo Nordisk.
Key trends studied for diabetes drug development in 2020 europeanpharmaceuticalreview
December 19, 2019
Functional links between metabolic, cardiovascular and renal diseases, as well as a focus on digital and a personalised approach will shape diabetes drug development in 2020, says new analysis.
A vaccine against chronic inflammatory diseases worldpharmanews
December 17, 2019
Chronic inflammatory bowel diseases, such as Crohn's Disease and ulcerative colitis, are linked to abnormalities of the gut microbiota in humans and in animals.
Azafaros B.V. Secures Seed Funding to Develop New Treatments in Rare Metabolic Disorders b3cnewswire
July 24, 2018
Azafaros, a biotech company established in Leiden in the Netherlands, focusing on the development of new therapies in the field of rare metabolic disorders, today announced the closing of a seed financing round. BioGeneration Ventures (BGV) is the foundin